nach oben

Seminars in Immunopathology

Erschienen in:

07.10.2019 | Review

Resolution of uveitis

verfasst von: Gerhild Wildner, Maria Diedrichs-Möhring

Erschienen in: Seminars in Immunopathology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune uveitis is a sight-threatening, rare disease, potentially leading to blindness. Uveitis is a synonym for intraocular inflammation, presenting as various clinical phenotypes with different underlying immune responses in patients, whereas different animal models usually represent one certain clinical and immunological type of uveitis due to genetic uniformity and the method of disease induction. T cells recognizing intraocular antigens initiate the disease, recruiting inflammatory cells (granulocytes, monocytes/macrophages) to the eyes, which cause the damage of the tissue. The treatment of uveitis so far aims at downregulation of inflammation to protect the ocular tissues from damage, and at immunosuppression to stop fueling T cell reactivity. Uveitis is usually prevented by specific mechanisms of the ocular immune privilege and the blood-eye-barriers, but once the disease is induced, mechanisms of the immune privilege as well as a variety of novel regulatory features including new Treg cell populations and suppressive cytokines are induced to downregulate the ocular inflammation and T cell responses and to avoid relapses and chronicity. Here we describe mechanisms of regulation observed in experimental animal models as well as detected in studies with peripheral lymphocytes from patients.

Rothova A, Suttorp van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332–336 Issn: 0007–1161CrossRefPubMedPubMedCentral

Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516CrossRefPubMed

Singh VK, Kalra HK, Yamaki K, Abe T, Donoso LA, Shinohara T (1990) Molecular mimicry between a uveitopathogenic site of S-antigen and viral peptides. Induction of experimental autoimmune uveitis in Lewis rats. J Immunol (Baltimore, Md : 1950) 144(4):1282–1287

Wildner G, Diedrichs-Möhring M (2003) Autoimmune uveitis induced by molecular mimicry of peptides from rotavirus, bovine casein and retinal S-antigen. Eur J Immunol 33(9):2577–2587. https://doi.org/10.1002/eji.200324058 CrossRefPubMed

Singh VK, Yamaki K, Donoso LA, Shinohara T (1989) Sequence homology between yeast histone H3 and uveitopathogenic site of S-antigen: lymphocyte cross-reaction and adoptive transfer of the disease. Cell Immunol 119(1):211–221CrossRefPubMed

Garip A, Diedrichs-Mohring M, Thurau SR, Deeg CA, Wildner G (2009) Uveitis in a patient treated with Bacille-Calmette-Guerin: possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology 116(12):2457–2462.e2451–2452. https://doi.org/10.1016/j.ophtha.2009.05.021 CrossRefPubMed

Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I (1985) Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci 26:1):1–1):9PubMed

Smith JR, Stempel AJ, Bharadwaj A, Appukuttan B (2016) Involvement of B cells in non-infectious uveitis. Clin Transl Immunol 5(2):e63–e63. https://doi.org/10.1038/cti.2016.2 CrossRef

Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim S-H, Egwuagu CE (2014) Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20:633–641. https://doi.org/10.1038/nm.3554 https://www.nature.com/articles/nm.3554#supplementary-information CrossRefPubMedPubMedCentral

10.

Dambuza IM, He C, Choi JK, Yu C-R, Wang R, Mattapallil MJ, Wingfield PT, Caspi RR, Egwuagu CE (2017) IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. Nat Commun 8(1):719–719. https://doi.org/10.1038/s41467-017-00838-4 CrossRefPubMedPubMedCentral

11.

Egwuagu CE, Yu C-R (2015) Interleukin 35-producing B cells (i35-Breg): a new mediator of regulatory B-cell functions in CNS autoimmune diseases. Crit Rev Immunol 35(1):49–57CrossRefPubMedPubMedCentral

12.

Davis JL, Solomon D, Nussenblatt RB, Palestine AG, Chan C-C (1992) Immunocytochemical staining of vitreous cells: indications, techniques, and results. Ophthalmology 99(2):250–256. https://doi.org/10.1016/S0161-6420(92)31984-0 CrossRefPubMed

13.

Hogan MJ, Wood IS, Godfrey WA (1973) Aqueous humor cytology in uveitis. JAMA Ophthalmol 89(3):217–220. https://doi.org/10.1001/archopht.1973.01000040219012 CrossRef

14.

Belfort R Jr, Moura NC, Mendes NF (1982) T and B lymphocytes in the aqueous humor of patients with uveitis. JAMA Ophthalmol 100(3):465–467. https://doi.org/10.1001/archopht.1982.01030030467019 CrossRef

15.

Wildner G, Hunig T, Thurau SR (1996) Orally induced, peptide-specific gamma/delta TCR+ cells suppress experimental autoimmune uveitis. Eur J Immunol 26(9):2140–2148. https://doi.org/10.1002/eji.1830260927 CrossRefPubMed

16.

Grégoire S, Terrada C, Martin GH, Fourcade G, Baeyens A, Marodon G, Fisson S, Billiard F, Lucas B, Tadayoni R, Béhar-Cohen F, Levacher B, Galy A, LeHoang P, Klatzmann D, Bodaghi B, Salomon BL (2016) Treatment of uveitis by in situ administration of ex vivo–activated polyclonal regulatory T cells. J Immunol 196(5):2109–2118. https://doi.org/10.4049/jimmunol.1501723 CrossRefPubMed

17.

Gilbert RM, Zhang X, Sampson RD, Ehrenstein MR, Nguyen DX, Chaudhry M, Mein C, Mahmud N, Galatowicz G, Tomkins-Netzer O, Calder VL, Lightman S (2018) Clinical remission of sight-threatening non-infectious uveitis is characterized by an upregulation of peripheral T-regulatory cell polarized towards T-bet and TIGIT. Front Immunol 9:907. https://doi.org/10.3389/fimmu.2018.00907 CrossRefPubMedPubMedCentral

18.

Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513CrossRefPubMed

19.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–796.e783. https://doi.org/10.1016/j.ophtha.2013.09.048 CrossRef

20.

Miserocchi E, Modorati G (2012) Rituximab for noninfectious uveitis. Dev Ophthalmol 51:98–109. https://doi.org/10.1159/000336188 CrossRefPubMed

21.

Tappeiner C, Heinz C, Specker C, Heiligenhaus A (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39(3):184–186. https://doi.org/10.1159/000103239 CrossRefPubMed

22.

Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 50(8):1390–1394. https://doi.org/10.1093/rheumatology/ker107 CrossRefPubMed

23.

Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V, Cimaz R (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 65(2):513–518. https://doi.org/10.1002/art.37776 CrossRefPubMedPubMedCentral

24.

Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197. https://doi.org/10.1007/s10067-016-3506-4 CrossRefPubMed

25.

Tappeiner C, Mesquida M, Adan A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicuna CG, Heiligenhaus A (2016) Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. 43(12) (0315-162X (Print)):2183–2188

26.

Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, Loricera J, González-Vela MC, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R (2017) Anti–interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis–associated uveitis refractory to anti–tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheum 69(3):668–675. https://doi.org/10.1002/art.39940 CrossRef

27.

Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, Pelegrín L (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251(11):2627–2632. https://doi.org/10.1007/s00417-013-2436-y CrossRefPubMed

28.

Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118(10):1916–1926. https://doi.org/10.1016/j.ophtha.2011.07.027 CrossRefPubMed

29.

Diedrichs-Möhring M, Niesik S, Priglinger CS, Thurau SR, Obermayr F, Sperl S, Wildner G (2018) Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells. J Neuroinflammation 15(1):54. https://doi.org/10.1186/s12974-018-1088-6 CrossRefPubMedPubMedCentral

30.

Diedrichs-Möhring M, Leban J, Strobl S, Obermayr F, Wildner G (2015) A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis: a new small molecule to treat monophasic and chronic EAU. Invest Ophthalmol Vis Sci 56(2):1147–1157. https://doi.org/10.1167/iovs.14-15518 CrossRef

31.

Bose T, Diedrichs-Mohring M, Wildner G (2016) Dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases. Autoimmun Rev 15(12):1181–1192. https://doi.org/10.1016/j.autrev.2016.09.001 CrossRefPubMed

32.

Wildner G, Diedrichs-Möhring M (2004) Autoimmune uveitis and antigenic mimicry of environmental antigens. Autoimmun Rev 3(5):383–387. https://doi.org/10.1016/j.autrev.2004.01.002 CrossRefPubMed

33.

Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, Chen J, Kielczewski JL, Silver PB, Jittayasothorn Y, Chan C-C, Yamane H, Honda K, Caspi RR (2015) Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity 43(2):343–353. https://doi.org/10.1016/j.immuni.2015.07.014 CrossRefPubMedCentralPubMed

34.

Charukamnoetkanok P, Fukushima A, Whitcup SM, Gery I, Egwuagu CE (1998) Expression of ocular autoantigens in the mouse thymus. Curr Eye Res 17(8):788–792CrossRefPubMed

35.

Kyewski B, Derbinski J (2004) Self-representation in the thymus: an extended view. Nat Rev Immunol 4(9):688–698. https://doi.org/10.1038/nri1436 CrossRefPubMed

36.

Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D (2002) Projection of an immunological self shadow within the thymus by the aire protein. Science 298(5597):1395–1401. https://doi.org/10.1126/science.1075958 CrossRefPubMed

37.

Shechter R, London A, Schwartz M (2013) Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol 13(3):206–218. https://doi.org/10.1038/nri3391 CrossRefPubMed

38.

Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3(11):879–889. https://doi.org/10.1038/nri1224 CrossRefPubMed

39.

Stein-Streilein J, Lucas K (2011) A current understanding of ocular immune privilege. Curr Immunol Rev 7(3):336–343. https://doi.org/10.2174/157339511796196683 CrossRef

40.

Taylor AW (2007) Ocular immunosuppressive microenvironment. Chem Immunol Allergy 92:71–85. https://doi.org/10.1159/000099255 CrossRefPubMed

41.

Taylor AW, Streilein JW, Cousins SW (1992) Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 11(12):1199–1206CrossRefPubMed

42.

Taylor AW, Yee DG (2003) Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 44(6):2644–2649CrossRefPubMed

43.

McPherson SW, Heuss ND, Gregerson DS (2013) Local “On-Demand” Generation and Function of Antigen-Specific Foxp3+ Regulatory T Cells. J Immunol 190(10):4971–4981. https://doi.org/10.4049/jimmunol.1202625 CrossRefPubMed

44.

Zhou R, Horai R, Silver PB, Mattapallil MJ, Zárate-Bladés CR, Chong WP, Chen J, Rigden RC, Villasmil R, Caspi RR (2012) the living eye “disarms” uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition. J Immunol 188(4):1742. https://doi.org/10.4049/jimmunol.1102415 CrossRefPubMed

45.

Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC (1993) Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 67(2):143–150CrossRefPubMed

46.

Thurau SR, Mempel TR, Flugel A, Diedrichs-Mohring M, Krombach F, Kawakami N, Wildner G (2004) The fate of autoreactive, GFP+ T cells in rat models of uveitis analyzed by intravital fluorescence microscopy and FACS. Int Immunol 16(11):1573–1582. https://doi.org/10.1093/intimm/dxh158 CrossRefPubMed

47.

Forrester JV, Huitinga I, Lumsden L, Dijkstra CD (1998) Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res 17(4):426–437CrossRefPubMed

48.

Rosenbaum JT (2016) Extraarticular manifestations: uveitis. In: Inman R, Sieper J (eds) Textbook of axial spondylarthritis, 1st edn. Oxford University Press, Oxford, pp 145–148

49.

Diedrichs-Mohring M, Hoffmann C, Wildner G (2008) Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. Int Immunol 20(3):365–374. https://doi.org/10.1093/intimm/dxm148 CrossRefPubMed

50.

von Toerne C, Sieg C, Kaufmann U, Diedrichs-Mohring M, Nelson PJ, Wildner G (2010) Effector T cells driving monophasic vs. relapsing/remitting experimental autoimmune uveitis show unique pathway signatures. Mol Immunol 48(1–3):272–280. https://doi.org/10.1016/j.molimm.2010.07.017 CrossRef

51.

Wildner G, Kaufmann U (2013) What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells. Autoimmun Rev 12(11):1070–1075. https://doi.org/10.1016/j.autrev.2013.04.001 CrossRefPubMed

52.

Kaufmann U, Diedrichs-Mohring M, Wildner G (2012) Dynamics of intraocular IFN-gamma, IL-17 and IL-10-producing cell populations during relapsing and monophasic rat experimental autoimmune uveitis. PLoS One 7(11):e49008. https://doi.org/10.1371/journal.pone.0049008 CrossRefPubMedPubMedCentral

53.

Diedrichs-Möhring M, Kaufmann U, Wildner G (2018) The immunopathogenesis of chronic and relapsing autoimmune uveitis – lessons from experimental rat models. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2018.02.003 CrossRefPubMed

54.

Lee YS, Amadi-Obi A, Yu C-R, Egwuagu CE (2011) Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 132(4):492–502. https://doi.org/10.1111/j.1365-2567.2010.03379.x CrossRefPubMedPubMedCentral

55.

Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD (2015) IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 14(12):1131–1141. https://doi.org/10.1016/j.autrev.2015.08.001 CrossRefPubMedPubMedCentral

56.

Takeda A, Hasegawa E, Fukuhara T, Hirakawa S, Yamada H, Yang Y, Yoshimura T, Hisatomi T, Oshima Y, Yoshida H, Sonoda KH, Ishibashi T (2014) EBI3 is pivotal for the initiation of experimental autoimmune uveitis. Exp Eye Res 125:107–113. https://doi.org/10.1016/j.exer.2014.06.004 CrossRefPubMed

57.

Sonoda KH, Yoshimura T, Takeda A, Ishibashi T, Hamano S, Yoshida H (2007) WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol 19(1):93–98. https://doi.org/10.1093/intimm/dxl125 CrossRefPubMed

58.

Adamus G, Manczak M, Machnicki M (2001) Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Investigative ophthalmology & visual science 42(12):2894–2903

59.

Chong WP, Horai R, Mattapallil MJ, Silver PB, Chen J, Zhou R, Sergeev Y, Villasmil R, Chan CC, Caspi RR (2014) IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun 50:12–22. https://doi.org/10.1016/j.jaut.2013.08.003 CrossRefPubMed

60.

Wang RX, Yu CR, Mahdi RM, Egwuagu CE (2012) Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem 287(43):36012–36021. https://doi.org/10.1074/jbc.M112.390625 CrossRefPubMedPubMedCentral

61.

Hashida N, Ohguro N, Nishida K (2012) Expression analysis of cytokine and chemokine genes during the natural course of murine experimental autoimmune uveoretinitis. ISRN Inflammation 2012:471617–471617. https://doi.org/10.5402/2012/471617 CrossRefPubMedPubMedCentral

62.

Owaki T, Asakawa M, Kamiya S, Takeda K, Fukai F, Mizuguchi J, Yoshimoto T (2006) IL-27 suppresses CD28-medicated IL-2 production through suppressor of cytokine signaling 3. J Immunol 176(5):2773–2780. https://doi.org/10.4049/jimmunol.176.5.2773 CrossRefPubMed

63.

Caspi RR, Chan CC, Grubbs BG, Silver PB, Wiggert B, Parsa CF, Bahmanyar S, Billiau A, Heremans H (1994) Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J Immunol (Baltimore, Md : 1950) 152(2):890–899 Issn: 0022–1767

64.

Hu MH, Zheng QF, Jia XZ, Li Y, Dong YC, Wang CY, Lin QY, Zhang FY, Zhao RB, Xu HW, Zhou JH, Yuan HP, Zhang WH, Ren H (2014) Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation. Clin Exp Immunol 175(2):268–284. https://doi.org/10.1111/cei.12219 CrossRefPubMedPubMedCentral

65.

Theodoropoulou S, Copland DA, Liu J, Wu J, Gardner PJ, Ozaki E, Doyle SL, Campbell M, Dick AD (2017) Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye. J Pathol 241(1):45–56. https://doi.org/10.1002/path.4816 CrossRefPubMed

66.

Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, Fukada SY, Besnard AG, Alves-Filho JC, Tong X, Forrester JV, Liew FY, Jiang HR (2014) IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol 44(11):3320–3329. https://doi.org/10.1002/eji.201444671 CrossRefPubMedPubMedCentral

67.

Rizzo LV, Miller Rivero NE, Chan CC, Wiggert B, Nussenblatt RB, Caspi RR (1994) Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 94(4):1668–1672 Issn: 0021–9738. https://doi.org/10.1172/JCI117511 CrossRefPubMedPubMedCentral

68.

Wang L, Yu CR, Kim HP, Liao W, Telford WG, Egwuagu CE, Leonard WJ (2011) Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci U S A 108(23):9542–9547. https://doi.org/10.1073/pnas.1018182108 CrossRefPubMedPubMedCentral

69.

Murray PJ (2006) Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 6(4):379–386. https://doi.org/10.1016/j.coph.2006.01.010 CrossRefPubMed

70.

Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19(1):683–765. https://doi.org/10.1146/annurev.immunol.19.1.683 CrossRefPubMed

71.

De Kozak Y, Thillaye Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C (2002) Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 130(2):212–223CrossRefPubMedPubMedCentral

72.

Smith JR, Verwaerde C, Rolling F, Naud MC, Delanoye A, Thillaye Goldenberg B, Apparailly F, De Kozak Y (2005) Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 16(9):1037–1046. https://doi.org/10.1089/hum.2005.16.1037 CrossRefPubMed

73.

Agarwal RK, Horai R, Viley AM, Silver PB, Grajewski RS, Bo Su S, Yazdani AT, Zhu W, Kronenberg M, Murray PJ, Rutschman RL, Chan C-C, Caspi RR (2008) Abrogation of anti-retinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms. J Immunol 180(8):5423–5429. https://doi.org/10.4049/jimmunol.180.8.5423 CrossRefPubMed

74.

Streilein JW, Okamoto S, Hara Y, Kosiewicz M, Ksander B (1997) Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen. Invest Ophthalmol Vis Sci 38(11):2245–2254PubMed

75.

Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW (2005) Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 46(3):908–919. https://doi.org/10.1167/iovs.04-0362 CrossRefPubMed

76.

Namba K, Kitaichi N, Nishida T, Taylor AW (2002) Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol 72(5):946–952PubMed

77.

Wildner G (2019) Are rats more human than mice? Immunobiology 224(1):172–176. https://doi.org/10.1016/j.imbio.2018.09.002 CrossRefPubMed

78.

Kitaichi N, Namba K, Taylor AW (2005) Inducible immune regulation following autoimmune disease in the immune-privileged eye. J Leukoc Biol 77(4):496–502. https://doi.org/10.1189/jlb.0204114 CrossRefPubMed

79.

Lee DJ, Taylor AW (2013) Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice. J Immunol (Baltimore, Md : 1950) 191(8):4103–4111. https://doi.org/10.4049/jimmunol.1300182 CrossRef

80.

Lee DJ, Taylor AW (2015) Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol 97(6):1101–1109. https://doi.org/10.1189/jlb.3A1014-466RR CrossRefPubMedPubMedCentral

81.

Lee DJ, Preble J, Lee S, Foster CS, Taylor AW (2016) MC5r and A2Ar deficiencies during experimental autoimmune uveitis identifies distinct T cell polarization programs and a biphasic regulatory response. Sci Rep 6:37790. https://doi.org/10.1038/srep37790 CrossRefPubMedPubMedCentral

82.

Silver P, Horai R, Chen J, Jittayasothorn Y, Chan C-C, Villasmil R, Kesen MR, Caspi RR (2015) Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol (Baltimore, Md : 1950) 194(7):3011–3019. https://doi.org/10.4049/jimmunol.1402650 CrossRef

83.

Jia X, Hu M, Wang C, Wang C, Zhang F, Han Q, Zhao R, Huang Q, Xu H, Yuan H, Ren H (2011) Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis. Mol Vis 17:1493–1507PubMedPubMedCentral

84.

Peng G, Guo Z, Kiniwa Y, Ks V, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang R-F (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309(5739):1380–1384. https://doi.org/10.1126/science.1113401 CrossRefPubMed

85.

Crane IJ, Kuppner MC, McKillop-Smith S, Knott RM, Forrester JV (1998) Cytokine regulation of RANTES production by human retinal pigment epithelial cells. Cell Immunol 184(1):37–44. https://doi.org/10.1006/cimm.1997.1235 CrossRefPubMed

86.

Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV (2000) Control of chemokine production at the blood-retina barrier. Immunology 101(3):426–433CrossRefPubMedPubMedCentral

87.

Ruggieri S, Frassanito MA, Dammacco R, Guerriero S (2012) Treg lymphocytes in autoimmune uveitis. Ocul Immunol Inflamm 20(4):255–261. https://doi.org/10.3109/09273948.2012.681830 CrossRefPubMed

88.

Yeh S, Li Z, Forooghian F, Hwang FS, Cunningham MA, Pantanelli S, Lew JC, Wroblewski KK, Vitale S, Nussenblatt RB (2009) CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol 127(4):407–413. https://doi.org/10.1001/archophthalmol.2009.32 CrossRefPubMedPubMedCentral

89.

Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang H-D, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5(2):e38. https://doi.org/10.1371/journal.pbio.0050038 CrossRefPubMedPubMedCentral

90.

Huehn J, Polansky JK, Hamann A (2009) Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 9:83–89. https://doi.org/10.1038/nri2474 CrossRefPubMed

91.

Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huehn J (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663. https://doi.org/10.1002/eji.200838105 CrossRefPubMed

92.

Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY (2010) Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463:808–812. https://doi.org/10.1038/nature08750 https://www.nature.com/articles/nature08750#supplementary-information CrossRefPubMedPubMedCentral

93.

Janson PCJ, Winerdal ME, Marits P, Thörn M, Ohlsson R, Winqvist O (2008) FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One 3(2):e1612. https://doi.org/10.1371/journal.pone.0001612 CrossRefPubMedPubMedCentral

94.

Kim Y, Kim TW, Park YS, Jeong EM, Lee D-S, Kim I-G, Chung H, Hwang Y-i, Lee WJ, Yu HG, Kang JS (2016) The role of interleukin-22 and its receptor in the development and pathogenesis of experimental autoimmune uveitis. PLoS One 11(5):e0154904. https://doi.org/10.1371/journal.pone.0154904 CrossRefPubMedPubMedCentral

95.

Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ (2009) The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10:595–602. https://doi.org/10.1038/ni.1731 https://www.nature.com/articles/ni.1731#supplementary-information CrossRefPubMedPubMedCentral

96.

Levine AG, Mendoza A, Hemmers S, Moltedo B, Niec RE, Schizas M, Hoyos BE, Putintseva EV, Chaudhry A, Dikiy S, Fujisawa S, Chudakov DM, Treuting PM, Rudensky AY (2017) Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature 546:421–425. https://doi.org/10.1038/nature22360 https://www.nature.com/articles/nature22360#supplementary-information CrossRefPubMedPubMedCentral

97.

Ohnmacht C, Park J-H, Cording S, Wing JB, Atarashi K, Obata Y, Gaboriau-Routhiau V, Marques R, Dulauroy S, Fedoseeva M, Busslinger M, Cerf-Bensussan N, Boneca IG, Voehringer D, Hase K, Honda K, Sakaguchi S, Eberl G (2015) The microbiota regulates type 2 immunity through RORγt T cells. Science 349(6251):989–993. https://doi.org/10.1126/science.aac4263 CrossRefPubMed

98.

Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM, Burzyn D, Ortiz-Lopez A, Lobera M, Yang J, Ghosh S, Earl A, Snapper SB, Jupp R, Kasper D, Mathis D, Benoist C (2015) Individual intestinal symbionts induce a distinct population of RORγt regulatory T cells. Science 349(6251):993–997. https://doi.org/10.1126/science.aaa9420 CrossRefPubMedPubMedCentral

Titel: Resolution of uveitis
verfasst von: Gerhild Wildner
Maria Diedrichs-Möhring
Publikationsdatum: 07.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Seminars in Immunopathology / Ausgabe 6/2019
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-019-00758-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Resolution of inflammation during multiple sclerosis

The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification

Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)

Resolution of inflammation: from basic concepts to clinical application

Resolution of neuroinflammation: mechanisms and potential therapeutic option